BiotechTube
Home/Nano Pharmasolutions/Kay Olmstead
KO

Kay Olmstead

CEO, Chief Executive Officer

Nano Pharmasolutions

Therapeutic Areas

Central Nervous System (CNS)Neurology

Nano Pharmasolutions Pipeline

DrugIndicationPhase
NT-301Neurological Disorder (Likely Parkinson's Disease)Phase 1
NT-401CNS DisorderPreclinical
NT-501CNS DisorderPreclinical

Leadership Team at Nano Pharmasolutions

JC
Justin Cho
Chief Business Officer
WM
William Martin
COO, Chief Operations Officer
SS
S. Shrewsbury
Chief Medical Officer
SK
Sam Koh
CTO, Chief Technology Officer
View full Nano Pharmasolutions profile